Los Angeles - 
(NewMediaWire) - May 26, 2021 - The Schall Law Firm, a national shareholder rights litigation firm,
announces that it is investigating claims on behalf of investors of FibroGen,
Inc. (“FibroGen” or “the Company”) (NASDAQ: FGEN) for violations of the securities laws.
The investigation focuses on whether the Company
issued false and/or misleading statements and/or failed to disclose information
pertinent to investors. FibroGen issued a statement on April 6, 2021, providing
“clarification of certain prior disclosures of U.S. primary cardiovascular
safety analyses from the roxadustat Phase 3 program for the treatment of anemia
of chronic kidney disease (‘CKD’).” The Company stated that its safety analysis
“included post-hoc changes to the stratification factors.” FibroGen disclosed
that based on analyses using the pre-specified stratification factors, the
Company “cannot conclude that roxadustat reduces the risk of (or is superior
to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to
epoetin-alfa.” Based on this news, shares of FibroGen dropped sharply.
If you are a shareholder who
suffered a loss, click here to
participate.
We also
encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.
The Schall Law Firm represents
investors around the world and specializes in securities class action lawsuits
and shareholder rights litigation.
This press release may be
considered Attorney Advertising in some jurisdictions under the applicable law
and rules of ethics.
CONTACT:
The Schall
Law Firm
Brian Schall, Esq.
310-301-3335
